Moreover, for more effective treatment of RA, antagonists of tumour necrosis factor alpha (TNF-α), interleukin 1 (IL-1), interleukin 6 (IL-6), and interleukin 17A (IL-17A) are also considered in treatment strategies, as these cytokines play important roles in the inflammatory process in RA [3]. This evidence concerns the gene IL17A and rheumatoid arthritis.